In last trading session, Global Blood Therapeutics Inc. (NASDAQ:GBT) saw 1.38 million shares changing hands with its beta currently measuring 1.22. Company’s recent per share price level of $27.73 trading at -$1.43 or -4.90% at ring of the bell on the day assigns it a market valuation of $1.77B. That closing price of GBT’s stock is at a discount of -89.29% from its 52-week high price of $52.49 and is indicating a premium of 11.25% from its 52-week low price of $24.61. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.1 million shares which gives us an average trading volume of 1.53 million if we extend that period to 3-months.
For Global Blood Therapeutics Inc. (GBT), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.90. Splitting up the data highlights that, out of 21 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 17 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.13 in the current quarter.
Global Blood Therapeutics Inc. (NASDAQ:GBT) trade information
Upright in the red during last session for losing -4.90%, in the last five days GBT remained trading in the red while hitting it’s week-highest on Wednesday, 01/12/22 when the stock touched $27.73 price level, adding 8.96% to its value on the day. Global Blood Therapeutics Inc.’s shares saw a change of -5.26% in year-to-date performance and have moved -2.39% in past 5-day. Global Blood Therapeutics Inc. (NASDAQ:GBT) showed a performance of 11.37% in past 30-days. Number of shares sold short was 7.15 million shares which calculate 3.77 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $70.32 to the stock, which implies a rise of 60.57% to its current value. Analysts have been projecting $38.00 as a low price target for the stock while placing it at a high target of $138.00. It follows that stock’s current price would drop -397.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of -37.04% for stock’s current value.
Global Blood Therapeutics Inc. (GBT) estimates and forecasts
Statistics highlight that Global Blood Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -12.99% of value to its shares in past 6 months, showing an annual growth rate of -13.61% while that of industry is 7.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -13.00% in the current quarter and calculating 9.10% increase in the next quarter. This year revenue growth is estimated to rise 56.70% from the last financial year’s standing.
19 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $55.04 million for the same. And 10 analysts are in estimates of company making revenue of $59.68 million in the next quarter that will end on Mar 2022. Company posted $41.3 million and $43 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 33.30% while estimating it to be 38.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.50% during past 5 years. In 2022, company’s earnings growth rate is likely to be around 11.80% while estimates for its earnings growth in next 5 years are of 37.00%.
Global Blood Therapeutics Inc. is more likely to be releasing its next quarterly report between February 22 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Global Blood Therapeutics Inc. (NASDAQ:GBT)’s Major holders
Insiders are in possession of 2.43% of company’s total shares while institution are holding 96.98 percent of that, with stock having share float percentage of 99.40%. Investors also watch the number of corporate investors in a company very closely, which is 96.98% institutions for Global Blood Therapeutics Inc. that are currently holding shares of the company. Janus Henderson Group PLC is the top institutional holder at GBT for having 6.27 million shares of worth $159.83 million. And as of Sep 29, 2021, it was holding 9.73% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 5.81 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 9.02% of outstanding shares, having a total worth of $148.15 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 1.95 million shares of worth $49.7 million or 3.03% of the total outstanding shares. The later fund manager was in possession of 1.78 million shares on Sep 29, 2021, making its stake of worth around $45.28 million in the company or a holder of 2.76% of company’s stock.